Decheng Capital Global Life Sciences Fund IV, L.P.
SEC insider (Form 3/4/5 filer). CIK 0001834150. 10% Owner at Aardvark Therapeutics, Inc. (AARD). 4 reported Form 4/5 transactions since Sep 2024; latest on Feb 14, 2025. Located in GRAND CAYMAN, E9.
Companies Decheng Capital Global Life Sciences Fund IV, L.P. has filed insider reports for
- Aardvark Therapeutics, Inc. (AARD): 10% Owner
Decheng Capital Global Life Sciences Fund IV, L.P.
CIK: 0001834150
Transaction Breakdown
Open Market Buys (P)2 (50.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (50.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AARD
Aardvark Therapeutics, Inc.
10% Owner
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Feb 14, 2025AARD
Aardvark Therapeutics, Inc.
ConversionIndirect2.3M shares- - Feb 14, 2025AARD
Aardvark Therapeutics, Inc.
ConversionIndirect333.4K shares- - Feb 14, 2025AARD
Aardvark Therapeutics, Inc.
PurchaseIndirect625K shares at avg. $16.00$10.0M - Feb 14, 2025AARD
Aardvark Therapeutics, Inc.
PurchaseIndirect625K shares at avg. $16.00$10.0M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 14, 2025 | AARD Aardvark Therapeutics, Inc. | Conversion | 2,333,887 | - | - | Indirect |
| Feb 14, 2025 | AARD Aardvark Therapeutics, Inc. | Conversion | 333,412 | - | - | Indirect |
| Feb 14, 2025 | AARD Aardvark Therapeutics, Inc. | Purchase | 625,000 | $16.00 | $10,000,000 | Indirect |
| Feb 14, 2025 | AARD Aardvark Therapeutics, Inc. | Purchase | 625,000 | $16.00 | $10,000,000 | Indirect |
1-4 of 4 transactions